Related Experiment Video
Updated: Feb 2, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
Targeting glycerophospholipid biosynthesis overcomes chemoresistance driven by SLFN11 loss in Ewing sarcoma
Kasturee Chakraborty1, Ritambhar Burman1, Saharsh Satheesh1
1Department of Radiology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Abstract:
Ewing sarcoma (EWS) is a highly aggressive pediatric malignancy characterized by elevated expression of SLFN11, which impairs DNA repair by binding to and functionally inhibiting DNA repair complexes, thereby enhancing susceptibility to genotoxic therapies. However, relapse remains a major clinical challenge and is often accompanied by the emergence of therapeutic resistance linked to reduced SLFN11 expression. We hypothesized that SLFN11-deficient tumors undergo adaptive metabolic reprogramming to overcome chemosensitivity. Here, we leverage transcriptomic and metabolomic profiling in patient-derived EWS models to demonstrate that SLFN11 loss drives downregulated mitochondrial glycerol-3-phosphate dehydrogenase (GPD2) expression, higher accumulation of glycerol-3-phosphate, fatty acid unsaturation, and enhanced glycerophospholipid (GPL) biosynthesis. Subsequently, targeting GPL biosynthesis (FSG67) restored DNA-damaging agent (SN-38) sensitivity in SLFN11-deficient EWS model, revealing a potential metabolic vulnerability to overcome chemoresistance. Furthermore, SLFN11 knockout tumors exhibited an elevated phosphocholine/glycerophosphocholine ratio, offering a potential non-invasive diagnostic biomarker.
Insights
Reduced SLFN11 expression in Ewing sarcoma (EWS) causes metabolic changes, leading to chemoresistance. Targeting glycerophospholipid biosynthesis can restore sensitivity, offering a new therapeutic strategy for EWS.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Research
Background:
- Ewing sarcoma (EWS) is an aggressive pediatric cancer.
- SLFN11 expression enhances sensitivity to genotoxic therapies.
- Therapeutic resistance in EWS is linked to reduced SLFN11 expression.
Purpose of the Study:
- To investigate the metabolic reprogramming in SLFN11-deficient EWS tumors.
- To identify metabolic vulnerabilities that can overcome chemoresistance in EWS.
- To explore potential non-invasive diagnostic biomarkers for EWS.
Main Methods:
- Transcriptomic and metabolomic profiling of patient-derived EWS models.
- Analysis of glycerol-3-phosphate dehydrogenase (GPD2) expression and glycerol-3-phosphate accumulation.
- Assessment of fatty acid unsaturation and glycerophospholipid (GPL) biosynthesis.
- Evaluation of therapeutic agents targeting GPL biosynthesis (FSG67) and DNA-damaging agents (SN-38).
Main Results:
- SLFN11 loss downregulated GPD2 expression, increased glycerol-3-phosphate, enhanced fatty acid unsaturation, and boosted GPL biosynthesis.
- Targeting GPL biosynthesis with FSG67 restored SN-38 sensitivity in SLFN11-deficient EWS models.
- SLFN11 knockout tumors showed an elevated phosphocholine/glycerophosphocholine ratio.
Conclusions:
- SLFN11-deficient EWS tumors exhibit metabolic reprogramming characterized by enhanced GPL biosynthesis, contributing to chemoresistance.
- Targeting GPL biosynthesis represents a potential strategy to overcome chemoresistance in EWS.
- The phosphocholine/glycerophosphocholine ratio may serve as a non-invasive diagnostic biomarker for EWS.
More Related Videos
Related Concept Videos
Biosynthesis in Bacteria
Biosynthesis of Polysaccharides
Biosynthesis of Lipids
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
Biosynthesis of Nucleic Acids
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

